Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 40c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.74), $0.40 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $166.8 million versus the consensus estimate of $197.77 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Penguin Solutions joins Nvidia AI Factory Specialized Partner program
• D-Wave Quantum (QBTS) call put ratio 5.3 calls to 1 put with a focus on July 26 and 30 calls as share price up 6.9%